Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov;75(5):1254-1256.
doi: 10.1016/j.jhep.2021.07.005. Epub 2021 Jul 10.

An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: Coincidence, autoimmunity or drug-related liver injury

Francesca Lodato  1 , Anna Larocca  2 , Antonietta D'Errico  3 , Vincenzo Cennamo  2
Affiliations
Comment

An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: Coincidence, autoimmunity or drug-related liver injury

Francesca Lodato et al. J Hepatol. 2021 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Francesca Lodato, Anna Larocca, Antonietta D’Errico and Vincenzo Cennamo declare no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.

Figures

Fig. 1
Fig. 1
Histology of liver biopsy. (A) H&E stain shows the histology of liver biopsy. The portal tract does not show fibrosis (C reticulin stain), but a moderate inflammatory infiltrate with interface hepatitis (arrow). The bile duct is surrounded by inflammatory cells and shows polymorphism of cholangiocytes (arrow). CK7 immunoreactivity is evident both in bile ducts and in hepatocytes (zone 1 and 2 blue arrow). (A,C,D 20x; B 60x).
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Bril F., Al Diffalha S., Dean M., Fettig D.M. Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty? J Hepatol. 2021 Jul;75(1):222–224. doi: 10.1016/j.jhep.2021.04.003. - DOI - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 Dec 31;383(27):2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Ehrenfeld M., Tincani A., Andreoli L., Cattalini M., Greenbaum A., Kanduc D., et al. Covid-19 and autoimmunity. Autoimmun Rev. 2020 Aug;19(8):102597. doi: 10.1016/j.autrev.2020.102597. - DOI - PMC - PubMed
    1. Zulfiqar A.A., Lorenzo-Villalba N., Hassler P., Andrès E. Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med. 2020 Apr 30;382(18):e43. doi: 10.1056/NEJMc2010472. - DOI - PMC - PubMed
    1. Bowles L., Platton S., Yartey N., Dave M., Lee K., Hart D.P., et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020 Jul 16;383(3):288–290. doi: 10.1056/NEJMc2013656. - DOI - PMC - PubMed

Substances